MBZIRC
28.9.2021 13:46:05 CEST | Business Wire | Press release
The Mohamed Bin Zayed International Robotics Challenge (MBZIRC) will be held in the UAE capital, Abu Dhabi, in June 2023, where tech innovators will participate to seek marine safety and security solutions to take home more than US$3 million in prize money.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005641/en/
Organised by ASPIRE, the dedicated technology programme management pillar of the Advanced Technology Research Council (ATRC), the overarching advanced technology research body in Abu Dhabi, UAE, the MBZIRC is held every two years. The upcoming edition, called MBZIRC Maritime Grand Challenge, focuses on real-time solutions to maritime safety and security challenges and seeks to claim its place among the largest and most prestigious AI and robotics competitions in the world.
The Challenge is open to international universities, research institutions, companies and individual innovators from all over the world. It will involve a heterogeneous collaboration among unmanned aerial vehicles and unmanned surface vehicles, to perform complex navigation and manipulation tasks in a GNSS-denied environment. Call for registrations is now open.
Commenting on the announcement, H.E. Faisal Al Bannai , Secretary General of ATRC, said: “We are proud that MBZIRC is going global by inviting the best talent from all over the world to participate. We have set a tough real-world challenge that will push the participants to the limits of their capabilities. The event is a great opportunity to demonstrate the pioneering scientific research work that is taking place in Abu Dhabi and the UAE.”
The challenge will show how both entities focus on niche areas of technology, while attracting global innovators to stimulate ideas, encourage collaboration, and push boundaries in advanced technologies to find systems solutions to global challenges.
“For countries with long coastlines, ensuring maritime safety requires significant investment in sophisticated equipment and highly trained personnel. Using advanced robotic systems can not only help reduce costs, but also handle some of the often- dangerous tasks performed by humans. The motivation for holding the MBZIRC Maritime Grand Challenge is to take the technology out of the laboratory and test it in a real-world environment to see what is possible,” said Dr Arthur Morrish, Chief Executive of ASPIRE.
Dr Morrish underscored the two-fold purpose behind the competition: one is to focus on the important problems in autonomy of robotics while engaging the world community in a hard robotics challenge. The other is to find a solution to a real-world challenge facing the world.
The challenge is for a swarm of UAVs to identify a target vessel from several similar vessels in open waters in a GNSS-denied environment, and to offload specific items from the target onto an USV in the shortest possible time using autonomous technologies. This is a new kind of kind of exercise in autonomous robotics. “A nice thing about this challenge is that you tell people what you want, but you don’t specify an approach to do it,” Dr Morrish added.
He said that this kind of a smart system will have practical application in other areas as well, especially as it can perform complex tasks of autonomous intervention in a GNSS-denied environment.
For more information, visit www.mbzirc.com
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005641/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla to Attend SuperReturn International 2026 to Advance Strategic Partnerships and Expand Its Presence in Global Private Capital8.6.2026 13:15:00 CEST | Press release
Xsolla Heads to Berlin to Advance and Foster Private Capital Relationships, Advance and Engage Senior Investors Across the Private Capital Ecosystem Xsolla, a global leader in video game commerce, today announced its participation in SuperReturn International 2026, taking place June 8–12 at the InterContinental Berlin. Uniting more than 6,000 senior attendees, including 2,000+ LPs and 3,000 GPs, SuperReturn International is widely recognized as the capital of private capital with the best investment opportunities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607269536/en/ Graphic: Xsolla The video game industry has matured into one of the largest and most resilient segments of the global entertainment economy, outpacing film and music combined, driving continuous growth through shifting market cycles. Yet the infrastructure powering how games are sold, monetized, and distributed worldwide remains under-examined
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
